Anebulo Pharmaceuticals, Inc.
SEC CIK 1815974 · ANEB · last insider filing 2025-04-07
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Aryeh Jason | Director | filed 2021 - 2025 |
| Shah Bimal R. | Director | filed 2023 - 2025 |
| Cunningham, Richard Anthony | Director · Chief Executive Officer | filed 2023 - 2025 |
| Lawler Joseph F. | Director | filed 2021 - 2025 |
| English Aron R. | Director | filed 2021 - 2025 |
| Lin Kenneth | Director | filed 2021 - 2025 |
| Kupchyk Areta | Director | filed 2021 - 2025 |
| Calloway Nathaniel | Director | filed 2022 - 2025 |
| Allen Simon | Director · Chief Executive Officer | filed 2022 - 2022 |
| Parschauer Karah Herdman | Director | filed 2021 - 2022 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Cundy Kenneth C | Chief Scientific Officer | filed 2022 - 2025 |
| George Dan | Chief Financial Officer | filed 2023 - 2023 |
| Gardiner Sandra A. | Acting Chief Financial Officer | filed 2023 - 2023 |
| Merchant James R. | Chief Financial Officer | filed 2021 - 2021 |
| Schneeberger Daniel | Chief Executive Officer | filed 2021 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.